Trial Profile

An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Target Total Therapy for Adult Ph-like Acute Lymphoblastic Leukemia

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Tucidinostat (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Idarubicin; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Vincristine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

01 Apr 2025 Results assessing he prognostic significance of MRD and IKZF1 in adult B-ALL patients receiving pediatric chemotherapy regimens published in the Transplantation and Cellular Therapy.
12 Dec 2023 Primary endpoint (Event free survival) has been met.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com